Benson R C
Mayo Clinic, Rochester, Minnesota.
Urologe A. 1991 May;30(3):158-61; discussion 161-2.
Photodynamic therapy (PDT) is a new and innovative approach to the treatment of malignant disease. This treatment modality involves administration of a photosensitizer, which is retained in malignant tissue, followed by exposure of that tissue to light corresponding to one of the absorption bands of the drug, with resultant cell death. Several photosensitizers are currently under study, but haematoporphyrin derivative (HPD) is the drug that has been used almost exclusively in clinical urological trials. Both direct and indirect methods have been used to document the preferential concentration or retention of HPD in malignant urothelium. Although this drug is not a perfect tumour localization aid, it is perhaps the best that has thus far been studied for transitional cell carcinoma of the bladder. Over the past decade of investigation, PDT has become established to the point that it is now being tested in phase II and III trials against standard and approved drugs for the treatment of noninvasive transitional cell carcinoma of the bladder.
光动力疗法（PDT）是一种治疗恶性疾病的全新创新方法。这种治疗方式包括给予一种光敏剂，该光敏剂会滞留在恶性组织中，随后将该组织暴露于与药物吸收带之一相对应的光线下，从而导致细胞死亡。目前有几种光敏剂正在研究中，但血卟啉衍生物（HPD）是几乎仅用于临床泌尿外科试验的药物。直接和间接方法都已被用于证明HPD在恶性尿路上皮中的优先浓度或滞留情况。尽管这种药物并非完美的肿瘤定位辅助剂，但它可能是迄今为止针对膀胱移行细胞癌研究得最好的药物。在过去十年的研究中，光动力疗法已发展到现在正在进行II期和III期试验，与用于治疗非侵袭性膀胱移行细胞癌的标准和已批准药物进行对比测试的阶段。
